Check which payment route applies

Ask the plan about the actual prescription

First record what medicine the clinician, the health professional assessing you, proposes and what it is meant to treat. Bring both to the insurance conversation. A plan’s answer about a drug for one purpose may not answer the question about another purpose.

Under the September 2026 rules, some prescriptions for purposes besides weight loss can qualify for Medicare Part D payment. Type 2 diabetes treatment is one example; reducing some serious heart risks is another. These are examples of medically accepted uses: uses the program recognizes for medical treatment. Your own plan still has to list the drug and approve any required request; a use that qualifies for coverage does not guarantee payment.

For example, semaglutide (Ozempic) injections are approved for type 2 diabetes, a use that can qualify for Part D under the September 2026 rules.

Medicare calls its drug benefit Part D. A formulary is a plan’s drug list. Prior authorization is an advance approval step the plan may require before paying. Ask whether the proposed product is on the list and what information the plan needs.

Ordinary Medicare Part D does not cover drugs used for weight loss under the law checked in September 2026. This exclusion depends on why the medicine is prescribed, rather than banning the medicine for every use.

Keep a record of the answer you receive and which product it concerns. Ask the clinician who can supply the information the plan requests. A statement that a service accepts insurance does not settle what your plan will pay.

Medicare’s weight-loss drug coverage page

Keep the temporary Medicare route in context

GLP-1 is one of the body’s hormones. Hormones carry messages; this one helps regulate blood sugar and appetite. Medicines that imitate it are often called GLP-1 medicines.

For eligible people, a monthly medicine supply through the temporary Medicare GLP-1 Bridge costs $50. It includes certain weight-loss medicines. The Centers for Medicare & Medicaid Services (CMS), Medicare’s agency, opened the program on July 1, 2026 and set December 31, 2027 as its end date.

The following eligibility rules were checked in September 2026. Ask the prescriber and your plan to compare them with your own records.

• The age requirement is 18 or older. The health tests use your circumstances when GLP-1 treatment began.
• You must have either a separate Part D plan for prescriptions or Medicare Advantage coverage in the coordinated-care category, with its drug benefit included. Ask which category your plan falls under; other coverage types need a separate qualifying Part D plan.
• A BMI score of 35 or higher meets the weight test. BMI means body mass index; it relates weight to height.
• A score of 30 or higher can meet the test with certain conditions. These are heart failure with preserved ejection fraction; chronic kidney disease at stage 3a or beyond; or uncontrolled blood pressure. For that blood-pressure category, the bottom number is still above 90 or the top number is still above 140 despite two blood-pressure medicines. Ask whether your heart-failure diagnosis has preserved ejection fraction.
• For a score from 27 upward, qualifying conditions include a previous stroke, pre-diabetes, an earlier heart attack or symptomatic peripheral artery disease. The last term means artery disease in a limb that produces symptoms.
• Having type 2 diabetes rules out this temporary program. So does moderate or severe obstructive sleep apnea, meaning breathing that is repeatedly blocked during sleep. Another exclusion is noncirrhotic MASH accompanied by moderate or advanced liver scarring. This means a particular fatty liver disease with scarring that has not reached cirrhosis, the most advanced stage. A different fatty liver diagnosis does not automatically exclude you. For these conditions, ask about ordinary Part D coverage instead. When the prescription’s purpose is reducing major risks to the heart and blood vessels, ordinary Part D is the payment route to ask about.
• One more test concerns earlier payment: if your GLP-1 was covered by Part D in 2026, Bridge enrollment is ruled out for that year. For the 2027 program, the September 2026 record contained no CMS decision about how far back to check earlier coverage.
• You need a prescription and prior authorization, meaning approval in advance. The prescription must be combined with ongoing lifestyle changes, including structured nutrition and physical activity.

The Bridge is a particular payment program, not a promise that all drugs in that group are included.

For September 2026, listed products are the KwikPen form of tirzepatide (Zepbound), orforglipron (Foundayo) tablets, and semaglutide (Wegovy) in tablets or injections.

For the Bridge in September 2026, spending on the copay earns no credit toward Part D out-of-pocket costs; coupons cannot be added.

These limits matter when comparing a program with ordinary plan coverage. Ask the clinician and the plan which payment route the proposed use belongs in. Use the official program page to check the detailed criteria rather than inferring eligibility from a headline.

CMS Bridge information and eligibility criteria

Separate savings cards from cash prices

Commercial insurance cards

In September 2026, manufacturer copay cards for branded GLP-1 medicines were limited to eligible people with private or workplace coverage, also called commercial insurance. They excluded people enrolled in government health programs.

Paying outside insurance

That restriction is different from manufacturer self-pay terms, which may permit people enrolled in government programs to pay the cash price.

Ask which offer is being discussed. Paying cash and using a card through commercial insurance are different arrangements. A low advertised copay does not tell you whether a card applies to your coverage or what another part of care will cost.

If you are comparing cash with insurance, ask for the full cash quote and the plan-specific answer. Keep the medication and visit charges separate, just as on the cost cards.

Leave with the payment question answered

Ask who will tell you if the plan declines payment, whether any charge has already been taken and what happens to an ongoing membership. If the person you reach handles only part of the bill, ask whom to contact for the rest.

The goal is a written explanation of the payment route in front of you. There is no need to decide from a starting price while the actual prescription and plan response are still unclear.